Darwin Wealth Management LLC Buys New Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Darwin Wealth Management LLC purchased a new position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 332 shares of the company’s stock, valued at approximately $31,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Grandfield & Dodd LLC grew its holdings in shares of GE HealthCare Technologies by 0.7% during the 3rd quarter. Grandfield & Dodd LLC now owns 322,889 shares of the company’s stock valued at $30,303,000 after purchasing an additional 2,101 shares during the last quarter. First Horizon Advisors Inc. increased its stake in shares of GE HealthCare Technologies by 8.4% in the third quarter. First Horizon Advisors Inc. now owns 5,950 shares of the company’s stock worth $558,000 after buying an additional 459 shares during the period. Advisors Asset Management Inc. boosted its position in GE HealthCare Technologies by 28.2% during the 3rd quarter. Advisors Asset Management Inc. now owns 97,430 shares of the company’s stock valued at $9,144,000 after buying an additional 21,413 shares during the period. Jennison Associates LLC grew its holdings in GE HealthCare Technologies by 56.4% in the 3rd quarter. Jennison Associates LLC now owns 761,618 shares of the company’s stock worth $71,478,000 after acquiring an additional 274,657 shares during the last quarter. Finally, Prospera Private Wealth LLC purchased a new position in shares of GE HealthCare Technologies in the third quarter valued at about $69,000. Institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Stock Performance

Shares of NASDAQ GEHC opened at $82.32 on Friday. GE HealthCare Technologies Inc. has a 1 year low of $66.39 and a 1 year high of $94.55. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.98. The stock has a market cap of $37.61 billion, a PE ratio of 22.62, a price-to-earnings-growth ratio of 2.96 and a beta of 1.24. The firm has a fifty day moving average price of $88.44 and a 200-day moving average price of $83.57.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.08. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The company had revenue of $4.86 billion for the quarter, compared to analysts’ expectations of $4.87 billion. During the same period in the previous year, the firm earned $0.99 EPS. The firm’s revenue was up .9% compared to the same quarter last year. Equities analysts anticipate that GE HealthCare Technologies Inc. will post 4.29 earnings per share for the current fiscal year.

GE HealthCare Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 15th. Stockholders of record on Friday, October 18th were issued a $0.03 dividend. The ex-dividend date of this dividend was Friday, October 18th. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.15%. GE HealthCare Technologies’s dividend payout ratio (DPR) is presently 3.30%.

Insider Activity

In related news, CEO Roland Rott sold 3,577 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the sale, the chief executive officer now owns 24,298 shares in the company, valued at approximately $2,101,291.04. This represents a 12.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

GEHC has been the topic of a number of research analyst reports. BTIG Research upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Wednesday, September 18th. Evercore ISI upped their target price on GE HealthCare Technologies from $98.00 to $102.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Stifel Nicolaus boosted their price objective on shares of GE HealthCare Technologies from $100.00 to $102.00 and gave the company a “buy” rating in a research report on Monday, September 30th. Wells Fargo & Company lifted their target price on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Finally, UBS Group lowered GE HealthCare Technologies from a “neutral” rating to a “sell” rating and dropped their price target for the company from $84.00 to $74.00 in a research report on Thursday, September 26th. One analyst has rated the stock with a sell rating, five have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $94.36.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.